Abstract
Purpose :
To analyze different tomographic characteristics and their influence in visual prognosis and need of treatment in patients with myopic choroidal neovascularization (CNV).
Methods :
We conducted a retrospective, observational study including all newly diagnosed patients with myopic CNV from May 2013 to May 2015, receiving antiangiogenic therapy with intravitreal ranibizumab injections in a pro re nata regime. Demographic data and visual acuity (VA) were collected. Optical coherence tomography (OCT) scans were evaluated analyzing the presence, or absence of a hyperreflective envelope around the neovascular tissue. Statistical analysis was performed with non-parametric test (Kruskal Wallis).
Results :
Twenty-seven eyes of 27 patients (mean age: 67,66 years +/- 11,42; 6 men: 21 women) were included. Sixteen patients were classified as group 1 (presence of hypereflective envelope; mean age: 68,27 years +/- 11,26; 5 men: 11 women); 5 patients were classified as group 2 (absence of the envelope; mean age: 69,25 years +/- 13,00; 5 women); 6 patients were classified as group 3 (mixed lesion; mean age: 64,72 years +/- 12,21; 1 man: 21 women). Mean baseline VA in logMAR was 0,82 (SD 0,95; 0,0-3,0) and final VA 0,42 (SD 0,43; 0,0-1,3); mean follow-up time was 10,66 months (SD 6,37; 0,0-27,37). No statistically significant differences were found between the 3 groups regarding the age (p=0.543), follow-up time (p=0.053), baseline VA (p=0,578), final VA (p=0,267), macular choroidal volume (p=0,904) and central choroidal thickness (p=0,883). Differences were observed in the total number of injections (p=0,01; Group 1: 1,8+/-1,1; Group 2: 2,69+/-1,14; Group 3: 3,33 +/-1,03). A statistically significant improvement between baseline and final VA was found only in Group 1 (p=0,006).
Conclusions :
We suggest a new anatomic tomographic classification in patients with myopic CNV based on the presence or absence of the hyperreflective envelope around the neovascular tissue. The presence of this sheath was related with a better visual prognosis with less number of intravitreal injections. Further studies are warranted in order to confirm these results.
This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.